Genetron Holdings Ltd. (GTH) – Globe Newswire
-
Genetron Health Announces Completion of Going Private Transaction
-
Genetron Health Announces Shareholders’ Approval of Merger Agreement
-
Genetron Health to Hold Extraordinary General Meeting of Shareholders
-
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
-
Genetron Health Announces Receipt of Notification from Nasdaq
-
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
-
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
-
Genetron Health Announces Receipt of Notification from Nasdaq
-
Genetron Health Announces Receipt of Notification from Nasdaq
-
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
-
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
-
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
-
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
-
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
-
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
-
Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day
-
Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day
-
Genetron Health Receives CAP Accreditation for its Maryland Laboratory
-
Genetron Health Receives CAP Accreditation for its Maryland Laboratory
-
Genetron Health Reports Unaudited First Quarter 2022 Financial Results
-
Genetron Health Reports Unaudited First Quarter 2022 Financial Results
-
Genetron Health Releases 10 New Research Results at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genetron Health Releases 10 New Research Results at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genetron Health Receives CE Mark for FusionScan Plus Kit for Human Multi-Genes
-
Genetron Health Receives CE Mark for FusionScan Plus Kit for Human Multi-Genes
-
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
-
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
-
Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®
-
Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®
-
Genetron Health Presents 17 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2022
-
Genetron Health Presents 17 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2022
-
Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™’s potential in MRD Assay Developments
-
Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™’s potential in MRD Assay Developments
-
Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results
-
Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results
-
Genetron Health to Participate in the Credit Suisse Asian Investment Conference
-
Genetron Health to Participate in the Credit Suisse Asian Investment Conference
-
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
-
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
-
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC
-
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC
-
Genetron Health to Participate in Upcoming Investor Conferences
-
Genetron Health to Participate in Upcoming Investor Conferences
-
Genetron Health Reiterates Full Year 2021 Revenue Guidance
-
Genetron Health Reiterates Full Year 2021 Revenue Guidance
-
Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible
-
Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible
-
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
-
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
-
Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
Back to GTH Stock Lookup
